
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Whether you are considering a new facility build or a facility upgrade, IPS has expert teams using the latest technologies to bring you strategies that provide cost certainty, real-time updates, and successful construction project management.






